Gilead Sciences (GILD) is back in focus after releasing new Phase 3 data for Livdelzi in primary biliary cholangitis, with results showing stronger ALP normalization and a consistent safety profile in inadequately controlled patients.

The recent Livdelzi updates arrive while Gilead’s share price has eased in the short term, with the stock down over the past month and quarter, yet still showing a 6.22% year to date share price return and a 17.34% 1 year total shareholder return that points to longer term momentum building behind the story.

If this kind of liver and autoimmune work has your attention, it can be worth seeing what else is emerging in healthcare related AI by scanning 38 healthcare AI stocks

With Gilead’s shares easing in recent weeks, yet still posting a 6.22% year to date gain and 17.34% 1 year total return, together with a sizeable discount to analyst and intrinsic values, is there a genuine opportunity here, or is the market already pricing in the next leg of growth?

Most Popular Narrative: 1% Overvalued

According to the most followed narrative, Gilead’s fair value sits at $128.38, just below the last close at $129.16, which implies a very tight gap between price and value.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers (lenacapavir, Trodelvy) and high-upside optionality (cell therapy, immunology). Temporary earnings headwinds from recent acquisitions may be masking longer term value creation as these platforms scale and begin to contribute more meaningfully to results.

Curious what earnings trajectory, margin profile and future profit multiple sit behind that near one to one price and value call? The narrative leans heavily on HIV cash flows, oncology ramp and a pipeline that assumes several key programs reach meaningful commercial scale.

Result: Fair Value of $128.38 (OVERVALUED)

However, investors still need to watch for clinical or regulatory setbacks in key programs, as well as any M&A integration stumbles that could weaken the earnings story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Cash Flows Point to a Different Story

While the popular narrative pegs Gilead as 1% overvalued at $128.38, our DCF model presents a different view, with a future cash flow value of $273.10 and the stock trading at a 52.7% discount. So which signal should matter more to you, sentiment or cash flows?

Next Steps

With sentiment split between opportunity and caution, it helps to move quickly, test the numbers yourself, and see what truly matters for your thesis. Then weigh up the 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If Gilead has sharpened your focus, do not stop here. Use the screener to quickly spot other stocks that fit the kind of portfolio you want to build.

• Chase potential upside in quality companies that trade below their estimated worth by scanning 48 high quality undervalued stocks
• Strengthen your income stream by reviewing stocks that offer resilient payouts through 10 dividend fortresses
• Sleep easier at night by checking companies that score well on resilience using the 63 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.